Mannan polysaccharides; high-molecular-weight mannan; fungal alpha-mannans; MUC1-mannan conjugate (investigational) · Evidence-based safety and harm-reduction overview.
| Also known as | Mannan polysaccharides; high-molecular-weight mannan; fungal alpha-mannans; MUC1-mannan conjugate (investigational) |
| Category | Research Chemical |
| Classification | Fungal/mammalian polysaccharide; pathogen-associated molecular pattern (PAMP) |
| Primary receptor | Dectin-2 (C-type lectin); also CD206 (mannose receptor) and DC-SIGN (CD209) |
| Key signaling pathway | FcRgamma - Syk - CARD9 - NF-kB; downstream IL-1beta and IL-23 secretion |
| Adaptive immune outcome | Th17 cell differentiation (preclinical); critical for host antifungal defense in mouse models |
| Development stage | Preclinical / early clinical (pilot trials only); no approved pharmaceutical product |
| Regulatory status (US) | No FDA approval; investigational/research material only |
| US legal status | No FDA approval. Alpha-mannans are not a marketed pharmaceutical or approved drug in the United States. They exist as research reagents and investigational materials only. Not regulated as a dietary supplement in any established category. Note: Velmanase alfa (Lamzede), an enzyme replacement therapy for the unrelated lysosomal storage disorder alpha-mannosidosis, is sometimes confused with alpha-mannans by name but is a distinct molecule; its US approval status is unclear from public data as of the knowledge cutoff. |
Alpha-mannans are a class of polysaccharides composed of mannose units found in the cell walls of fungi such as Candida albicans and on mammalian cell-surface glycoproteins as high-mannose N-linked glycans. They are not a single defined drug entity or a commercial pharmaceutical product. Research interest centers on their role as pathogen-associated molecular patterns (PAMPs) that activate innate immune signaling, with investigational application as vaccine adjuvants and immunotherapy conjugates. No alpha-mannan product has reached regulatory approval or active late-stage clinical development.
Alpha-mannans are recognized primarily by Dectin-2, a C-type lectin receptor expressed on dendritic cells and macrophages. Dectin-2 engagement signals through the FcRgamma chain, activating Syk kinase and the CARD9 adaptor, which drives NF-kB activation and downstream secretion of IL-1beta and IL-23. This cytokine milieu promotes Th17 cell differentiation, an adaptive immune response critical for mucosal antifungal defense - IL-17A-deficient mice show markedly increased susceptibility to systemic Candida infection in preclinical models. Alpha-mannans also engage the mannose receptor (CD206) and DC-SIGN (CD209), which may modulate tolerogenic versus inflammatory outcomes depending on context. Their immunostimulatory properties have prompted investigation as adjuvants to enhance antigen-specific immune responses in conjugate vaccine platforms.
Alpha-mannans were identified as immunologically active components of fungal cell walls in the latter decades of the 20th century, initially studied in the context of host defense against Candida and other opportunistic fungi. Academic immunology groups, including NIH-affiliated and European university laboratories, characterized the Dectin-2 signaling axis in animal models during the 2000s and 2010s. Separately, cancer immunotherapy researchers explored mannan conjugation strategies to enhance tumor antigen immunogenicity, including a pilot trial combining mannan with the breast cancer antigen MUC1. A grass pollen allergoid-mannan conjugate was evaluated in a completed allergen immunotherapy trial (ClinicalTrials.gov NCT02654223). No single pharmaceutical company has emerged as the primary developer; the field remains distributed across academic and preclinical settings with no major commercial pipeline identified in public databases.
Preclinical and very early clinical stage only. Mechanistic work in mouse models has firmly established the Dectin-2/CARD9/Th17 axis for fungal PAMPs. Cancer vaccine pilot data used a MUC1-mannan conjugate in a small breast cancer cohort - evidence is exploratory and insufficient to draw efficacy conclusions. A completed phase I/II allergen immunotherapy trial (NCT02654223) tested a grass pollen allergoid conjugated to mannan; results have been published but represent a single completed study in a narrow indication. No phase III trials for alpha-mannans as a standalone agent have been identified in public registries. The bulk of available data is animal-model mechanistic work and small early-phase human signals. Efficacy for any therapeutic indication in humans is unestablished.
No established human dosing exists for alpha-mannans as a therapeutic or investigational agent outside formally designed clinical trials. Literature reports use conjugate preparations at concentrations determined per study protocol in highly controlled settings. This information is presented for reference purposes only and does not constitute a dosing recommendation or protocol. Consult a licensed clinician before considering any investigational agent.
This is general research/context information, not medical advice or a recommended protocol.
No evidence base for combining alpha-mannans with other compounds in a human context. Conjugate vaccine research has paired alpha-mannans with protein antigens (MUC1, grass pollen allergoid) as an adjuvant strategy in controlled trial settings only. No stack data exists outside those protocols.
Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.
Get tested with Ulta Lab Tests →No. Alpha-mannans are not approved by the FDA as a drug or classified as a recognized dietary supplement. They exist as research reagents and have been tested in small early-phase clinical trials as vaccine adjuvants, but no product has reached approval in any major jurisdiction.
Primarily as an immunostimulatory adjuvant in conjugate vaccine research (cancer antigens, allergen immunotherapy) and as a tool to study innate immune signaling through Dectin-2 and related C-type lectin receptors. Its role in antifungal host defense is also an active area of basic science investigation.
No. Velmanase alfa is a recombinant human alpha-mannosidase enzyme used to treat alpha-mannosidosis, a rare lysosomal storage disorder. Despite the name overlap, it is a completely distinct molecule from alpha-mannan polysaccharides and the two should not be confused.
There is no established or recommended human dose for alpha-mannans outside of formally designed clinical trial protocols. This question cannot be answered safely in a general reference context. Consult a licensed clinician or research physician.
Very limited. The mechanistic foundation comes primarily from preclinical animal models. Human data is restricted to small pilot trials of conjugate preparations (MUC1-mannan in breast cancer, allergoid-mannan in grass pollen allergy), none of which establish efficacy in any indication. The overall evidence base is exploratory.
They are structural components of the outer cell wall of fungi including Candida albicans and related species, and are also found as high-mannose N-linked glycans on mammalian cell-surface glycoproteins. They are not a synthetic compound but rather a class of naturally occurring polysaccharides.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.